linjc16/ctgov huggingface dataset:
Arthroscopic Release Of Shoulder Internal Rotation Contracture In Brachial Plexus Palsy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy periarticular capsuloligamentous arthroscopic release of shoulder internal rotation contracture in brachial plexus palsy without any further intervention as tendon transfer.

Detailed Description
-----------------
Obstetrical brachial plexus paralysis (OBPP) refers to complete or partial injury of the brachial plexus produced at the time of birth. OBPP involves most commonly the upper cervical roots (C5, C6) resulting in muscle imbalance between internal and external rotators of the shoulder . Although the majority of the patients (80-90%) recover spontaneously, some have a remaining imbalance causing severe functional impairment . In addition to diminished function, prolonged muscle contractures result in bony deformities in both the glenoid and proximal humerus. Internal rotation contractures due to external rotational weakness are the most common deformity in OBPP. Contracture release, tendon transfers, and rotational osteotomies are surgical methods used, depending on the level of deformity and the patient's age. To achieve functional external rotation of the arm, contracted structures should be released first. Currently, there is a lack of consensus on which procedures over the best outcome for mobility and function, and what are the precise indications for each type of surgery. There is also a large variation of practice between centers

Official Title
-----------------
Arthroscopic Release Of Shoulder Internal Rotation Contracture In Brachial Plexus Palsy

Conditions
-----------------
Arthroscopy

Intervention / Treatment
-----------------
* Device: ARTHROSCOY


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children from 1 year to 15years of age. all genders patients with brachial plexus injury operated or not with internal rotation contracture patient with traumatic brachial plexus injury have residual internal rotation contracture Exclusion Criteria: History of septic shoulder Flail anaethetic limb glenohumeral posterior sublaxation or dislocation in CT

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: ARTHROSCOY|arthroscopy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with failure of initial intervention | change of improvement of passive and active external rotation of operated shoulder using mallet score | 1 year |
Sarcopenic Obesity in the Elderly

Study Overview
=================
Brief Summary
-----------------
Ageing is associated with progressive and generalized loss of muscle mass and muscle function, also known as Sarcopenia. Increasingly, obesity has become a compounding factor in ageing-related sarcopenia. The coexistence of obesity and sarcopenia is termed sarcopenic obesity (SO). Older adults with SO are at higher risks of developing diabetes, hypertension, stroke, cardiovascular diseases, and cognitive dysfunction than those older adults who suffer from sarcopenia alone or obesity alone. However, there is insufficient information with regard to the interplay between obesity and sarcopenia. The primary objective of this study is to investigate the impact of SO on insulin resistance in people aged 65-85. Our hypothesis is that SO positively influences insulin resistance in the elderly. We propose to investigate sarcopenia and obesity as risk factors for insulin resistance in the geriatric (65-85 years old) population.

Official Title
-----------------
Sarcopenic Obesity as Risk Factor for Insulin Resistance in the Elderly

Conditions
-----------------
Sarcopenic Obesity, Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: This study will include both male and females aged 65-85 years. Exclusion Criteria: Lack capacity to consent for the study, or have moderate or severe cognitive impairment; Have difficulty ambulating as evidenced by any one of the following: Difficulty climbing 10 steps without resting; Restricted to a wheelchair Have difficulty performing basic activities of daily living; Have had treatment for cancer in the prior 3 years; Have history of cachexia; Have a history of heart failure; Have a permanent pacemaker in situ (due to magnetic resonance scanning); Have an implanted cardioverter-defibrillator (ICD) in situ; Have had myocardial infarction within the last 6 months; Have any of the following chronic health conditions: peripheral arterial disease prostate cancer, rheumatoid arthritis, autoimmune myositis, chronic obstructive pulmonary disease, and asthma; Are receiving therapy with corticosteroids or immunosuppressants. Are taking direct insulin sensitizers (PPAR-gamma agonists, or thiazolidinediones).

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To explore the correlation of sarcopenia and obesity on insulin resistance |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To explore the correlation between muscle strength and memory loss |  | 2 years | 
| To explore the correlation of sarcopenic obesity and glucometabolic and cardiovascular risk. |  | 2 years |
Pterygopalatine Fossa Block in Aneurysmal Subarachnoid Hemorrhage

Study Overview
=================
Brief Summary
-----------------
Aneurysmal subarachnoid hemorrhage (aSAH) can cause a severe headache (HA) that is famously treatment-resistant. Current pain regimens are too reliant on opioids, which results in long-term opioid dependence and can obfuscate the neurological examination, which is critical to detect vasospasm and delayed cerebral ischemia. This study will gather the initial evidence of whether the pterygopalatine fossa (PPF) regional anesthesia nerve block can treat aSAH-related HA and reduce opioid consumption in patients with aSAH.

Official Title
-----------------
Pterygopalatine Fossa Block in Aneurysmal Subarachnoid Hemorrhage

Conditions
-----------------
Subarachnoid Hemorrhage, Aneurysmal

Intervention / Treatment
-----------------
* Procedure: Ptergyopalatine Fossa Block
* Drug: Bupivacaine 0.25% Injectable Solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aneurysmal subarachnoid hemorrhage with secured aneurysm Age greater than or equal to 18 years Able to communicate pain level Exclusion Criteria: Documented allergy to local anesthetics (e.g. bupivicaine) Patients with unsecured aneurysms Patients who are unable to communicate pain level (e.g. sedation/mechanical ventilation/delirium, etc) Medical treatment for vasospasm including blood pressure/inotropic augmentation Angiographic treatment for vasospasm within 48 hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment arm<br> | Procedure: Ptergyopalatine Fossa Block<br>* Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage<br>Drug: Bupivacaine 0.25% Injectable Solution<br>* Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Opioid consumption |  | 3 days | 
| Pain Rating Scale | Scale of 1-10, 1 being lowest possible pain, 10 being highest possible pain | 3 days |
Cystic Fibrosis and Frailtyh What's in Common?

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to assess the main clinical and anamnestic characteristics, and frailty syndrome in an adult Cystic Fibrosis population. The main question it aims to answer is the possible association of the frailty status with the main clinical, therapeutical characteristics, including the genotyping classification of Cystic Fibrosis patients.

Detailed Description
-----------------
Participants will be assessed for the pulmonary status by spirometry (for Forced Expiratory Volume in 1 second [FEV1 - L]; Forced Expiratory Volume in 1 second percent predicted [ppFEV1%]; Forced Vital Capacity [FVC - L]; Forced Vital Capacity percent predicted [FVC %]; Maximal Mid-Expiratory Flow [MMEF]); for the functional status by evaluating the activities of daily living [ADLs], and the instrumental ADLs [IADLs]; and for frailty by the Study of Osteoporotic Fractures [SOF] Index. The height and weight will be also recorded, and Body Mass Index [BMI] calculated as body weight divided by height squared [Kg/m2]. Body weight will be measured in a fasting state in the morning with a mechanical balance.

Official Title
-----------------
Cystic Fibrosis in Adults and Frailty

Conditions
-----------------
Frailty Syndrome, Cystic Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: who met the diagnostic criteria for CF, over 18 years old, pathological sweat chloride levels (chloride >60 mEq/L) and two CFTR mutations Exclusion Criteria: who did not meet the diagnostic criteria for CF under 18 years old over 18 years old with normal sweat chloride levels (chloride >60 mEq/L)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adults with Cystic Fibrosis<br>All patients who met the diagnostic criteria for CF, over 18 years old, with pathological sweat chloride levels (chloride >60 mEq/L) and two CFTR mutations were recruited. Sweat chloride levels have been tested, and a panel of CFTR mutations screened. The CFTR genotype has been defined through the screening of the most frequent mutations and rearrangements. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pre-Frail/Frail Status | Frailty has been assessed by the SOF Index | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
functional status, frailty, Cystic Fibrosis, geriatric syndrome
Shear-wave Elastography of Hip Stabilizers in Healthy Individuals

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to provide a scientific basis for Shear-wave elastography measurements of hip stabilizing muscles on healthy individuals. To assess the inter- and intra-user validity, 12 healthy volunteers were recruited for ultrasonographic assessment by two experienced physiatrists.

Official Title
-----------------
Reliability of Ultrasound Shear-wave Elastography in Assessing Tensor Fascia Lata, Gluteus Medius, and Iliotibial Band Elasticity in Health Individuals: a Cross-sectional Study.

Conditions
-----------------
Shear-wave Elastography of Hip Stabilizers in Healthy Individuals

Intervention / Treatment
-----------------
* Diagnostic Test: Shear-wave elastography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Individuals Age 18-30 years Volunteering for the study Absence of musculoskeletal pathologies involving pelvic, hip, and/or knee joints. Exclusion Criteria: Recent complaints of pelvic, hip, and/or knee pain. Previous history of trauma or surgery, including the lumbar, pelvic, hip, or knee region. Congenital or acquired pathologies of pelvis or lower extremity.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy Individuals<br> | Diagnostic Test: Shear-wave elastography<br>* Shear-wave elastography using a manual ultrasound with a 9L-Probe in B-mode.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of tensor fascia latae muscle on shear wave elastography. |  | 1 month | 
| Assessment of gluteus medius muscle on shear wave elastography. |  | 1 month | 
| Assessment of iliotibial band on shear wave elastography. |  | 1 month |
Portal Hypertension Using Magnetic Resonance Elastography

Study Overview
=================
Brief Summary
-----------------
This prospective study was conducted in a tertiary university hospital. The investigators researched the correlation between MRE-assessed stiffness of the liver and spleen and the Hepatic venous pressure gradient (HVPG) values. Furthermore, the investigator evaluated whether MRE-assessed stiffness reflected changes in portal hypertension (PH) after administering non-selective beta-blockers (NSBBs).

Official Title
-----------------
Non-invasive Assessment of Portal Hypertension Using Quantitative Magnetic Resonance Imaging

Conditions
-----------------
Portal Hypertension, Magnetic Resonance Imaging

Intervention / Treatment
-----------------
* Diagnostic Test: MRE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed liver cirrhosis requiring prophylactic treatment of esophageal varices Exclusion Criteria: the coexistence of hepatocellular carcinoma refractory ascites who regularly underwent large-volume paracentesis the use of selective beta-blocker or carvedilol therapy for at least 4 weeks undergoing liver transplantation contraindication with magnetic resonance imaging

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: MRE|MRE was performed using a 3T system (Magnetom Skyra; Siemens, Erlangen, Germany) equipped with a combination of a 30-channel body and a 32-channel spine matrix coil.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of liver stiffness and spleen stiffness by MRE |  | Change from baseline stiffness of MRE at 6 months | 
| The change of portal pressure (HVPG) prior to and after treatment with NSBB |  | Change from baseline and at 6 months |
Cognitive, Motor and Sleep Evaluation in Patients With Ischemic Stroke of Basal Ganglia After Thrombectomy

Study Overview
=================
Brief Summary
-----------------
The goal of this interventional study is to learn about the clinical outcomes of acute ischemic stroke treated with mechanical thrombectomy resulting in a selective ischemia of the basal ganglia. The main question it aims to answer is: • defining the prevalence and clinical features of possible cognitive, motor and sleep disfuncions occuring after acute ischemic stroke treated with thrombectomy Participants will be tested for cognitive, movement and sleep disorders in the acute phase and successively in the long term follow-up.

Official Title
-----------------
Cognitive, Motor and Sleep Evaluation in Patients With Ischemic Stroke of Basal Ganglia After Thrombectomy

Conditions
-----------------
Post-stroke Disorders

Intervention / Treatment
-----------------
* Device: polysomnography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: participant's age ≥ 18 years acute ischemic stroke due to occlusion of proximal middle cerebral artery successfully treated with mechanical thrombectomy (mTICI ≥ 2B) signature of specific written informed consent Exclusion Criteria: unstable clinical conditions personal history of cognitive decline before the acute ischemic stroke

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients affected by acute ischemic stroke treated with mechanical thrombectomy<br> | Device: polysomnography<br>* Sleep study through polysomnographic examination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-stroke cognitive dysfunction | Assessment through the MoCA (Montreal Cognitive Assessment) score of cognitive dysfunction in patients with acute ischemic stroke treated with mechanical thrombectomy | Within 72 hours |
State of Play of Non-tuberculous Mycobacteria in Alsace

Study Overview
=================
Brief Summary
-----------------
Non-tuberculous mycobacteriosis (NTM) are infectious diseases caused by mycobacteria that are not part of the Tuberculosis complex. More than 190 species have been identified to date. As an environmental reservoir, it most often affects the lungs, skin and soft tissues, lymph nodes, but it can affect all organs. Varying in virulence depending on the species, most infections do not cause illness. There is currently no coordinated care pathway for this pathology in Alsace. The means necessary to set up such a structure requires knowing the importance of the disease.

Detailed Description
-----------------
The aim of the study is to determine the incidence of non-tuberculous mycobacterial infections in the ALSACE region, the proportion of cases in which the infection causes illness, and its evolution over time.

Official Title
-----------------
State of Play of Non-tuberculous Mycobacteria in Alsace: a Retrospective Study

Conditions
-----------------
Non-Tuberculous Mycobacteria

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult subject (≥ 18 years old) in whom a biological sample is culture positive for a non-tuberculous mycobacterium born in France and domiciled in Alsace (i.e. whose home postal code begins with 67 or 68) not opposing the reuse of its data for scientific research purposes Exclusion Criteria: Subject having expressed opposition to participating in the study not domiciled in Alsace Born abroad Isolation of a mycobacterium from the Tuberculosis complex and Mycobacterium gordonae

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective description of non-tuberculous mycobacteria in Alsace |  | Through study completion, an average of 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-Tuberculous Mycobacteria
Deep Learning OCT and OCTA in NVC

Study Overview
=================
Brief Summary
-----------------
To evaluate the activity of neovascular macula degeneretion as assessed by SD-OCTand OCT-A using a split-person study design and deep-learning quantification.

Detailed Description
-----------------
Exudative neovascular macular degeneration is the primarily an age-related retinal condition The optical coherence tomography angiography represents a novel and noninvasive diagnostic technique that allows a detailed and quantitative analysis of retinal and choriocapillary vascular features in order to choose the best therapy . The study evaluates the changes in structural optical coherence tomography and optical coherence tomography angiography features in neovascular macular degeration patients undergoing ANTI-VEGF treatments using artificial intelligence.

Official Title
-----------------
Deep Learning OCT and OCTA Quantification in Neovascular Age Related Macular Degeneration

Conditions
-----------------
Macular Degeneration Choroidal Neovascularization

Intervention / Treatment
-----------------
* Diagnostic Test: Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age older than 50 years diagnosis of neovascular macular degeneration absence of previous retinal surgery and congenital eye diseases. absence of errors of refraction absence of lens opacities absence of low-quality OCT and OCTA images Exclusion Criteria:• age younger than 50 years previous retinal surgery and congenital eye diseases errors of refraction lens opacities low-quality OCT and OCTA images

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with neovascular macular degeneration<br> | Diagnostic Test: Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter<br>* Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter before and after ANTI-VEGF treatment<br>|
| healty patients matched age and sex without any ocular disease<br> | Diagnostic Test: Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter<br>* Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter before and after ANTI-VEGF treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The measurements of retinal and choriocapillary vessel density in patients with macular degeneration complicated by nvc |  | more than sixmonths |